2019
DOI: 10.1111/aor.13466
|View full text |Cite
|
Sign up to set email alerts
|

Renal support: A time to reassess the direction!

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
7
0

Year Published

2020
2020
2022
2022

Publication Types

Select...
6

Relationship

1
5

Authors

Journals

citations
Cited by 7 publications
(7 citation statements)
references
References 8 publications
0
7
0
Order By: Relevance
“…In addition, clinical experience suggests that the time dynamics of eGFR decline may also be different with many patients remaining in stable clinical status for several years with a low but stable eGFR while others experience a more rapid decline or become symptomatic at relatively high eGFR. As pointed out in a recent Editorials in this journal as well, after a period of relative stagnation in the last few decades, innovation and new initiatives are challenging the inertia and current practice of renal replacement therapies and prevention of progressive renal diseases 8 and new, disruptive technological innovation in renal medicine is likely to emerge soon 9 . In such context, it is critical to be able to recognize the potential disconnect between safety and efficacy of a single session (or period) of therapy and the patients’ global well‐being and state of health.…”
Section: Introductionmentioning
confidence: 99%
“…In addition, clinical experience suggests that the time dynamics of eGFR decline may also be different with many patients remaining in stable clinical status for several years with a low but stable eGFR while others experience a more rapid decline or become symptomatic at relatively high eGFR. As pointed out in a recent Editorials in this journal as well, after a period of relative stagnation in the last few decades, innovation and new initiatives are challenging the inertia and current practice of renal replacement therapies and prevention of progressive renal diseases 8 and new, disruptive technological innovation in renal medicine is likely to emerge soon 9 . In such context, it is critical to be able to recognize the potential disconnect between safety and efficacy of a single session (or period) of therapy and the patients’ global well‐being and state of health.…”
Section: Introductionmentioning
confidence: 99%
“…• Consider referring to the ISN roadmap for Prevention aspects: It is time to reassess directions within the renal field. 25 To formulate medically meaningful and commercially viable product milestones, one first needs to consider possible disease prevention strategies before elaborating upon any therapeutic technology. This starts with efforts toward earlier diagnosis.…”
Section: Possible Next Steps For Khi Considerationmentioning
confidence: 99%
“…Clearly, the demand does not meet the need in the United States and worldwide, and the burden of treatment for end‐stage kidney disease falls on dialysis, a treatment on which there are now over 2 million patients worldwide. Such therapies are financially unsustainable even for the developed world, 19 and it is time to reassess the direction of renal support 20 . Technologies and approaches to dialysis therapy vary across the world with different outcomes.…”
Section: Reflections On Renal Supportmentioning
confidence: 99%